340B ESP and HIPAA Compliance - McDermott Will & Emery

340B ESP and HIPAA Compliance


Many pharmaceutical manufacturers currently require 340B covered entities to provide de-identified pharmacy claims data for dispensed 340B drugs to a third party, 340B ESP, as a condition of receiving discounts under the 340B program. Although the claims data may be de-identified in the hands of 340B ESP, pharmaceutical manufacturers can link the data to identifiable rebate transactions to determine if pharmacy benefit managers (PBMs) have obtained rebates for previously discounted medications. This re-identification of the data, which manufacturers have been transparent about, has caused some 340B covered entities to question the permissibility of the 340B ESP data submission under the Health Insurance Portability and Accountability Act of 1996 (HIPAA).

Access the slides here.

Dig Deeper

Miami, FL / McDermott Event / March 6-7, 2024

HPE Miami 2024

New York, NY / McDermott Event / October 13, 2023

HPE NYC 2023

London, UK / McDermott Event / September 21, 2023

HPE Europe 2023

London / ABHI / July 11, 2023

ABHI Women in Leadership Networking Event

San Francisco, CA / McDermott Event / June 27, 2023

AHLA Annual Meeting Reception 2023

San Francisco, CA / AHLA / June 26 - 28, 2023

AHLA Annual Meeting 2023

Get In Touch